Drug Repurposing of Rapamycin Mitigates Amyloid-β-Associated Proteotoxicity in Caenorhabditis elegans Models of Alzheimer's Disease
Drug Repurposing of Rapamycin Mitigates Amyloid-β-Associated Proteotoxicity in Caenorhabditis elegans Models of Alzheimer's Disease
New Results
, Abdullatif Alsulami, Makayla Linfoot, Megan Terlouw, Ava Holzer, Faisal Albalawi, Stephanie McGrath, Julie Moreno
doi: https://doi.org/10.64898/2026.11.14.766704
Abstract
Background: Alzheimers disease (AD) is the leading cause of dementia worldwide, affecting an estimated 55 million people and projected to exceed 130 million by 2050. AD is defined pathologically by extracellular accumulation of amyloid-beta (Aβ) and intracellular neurofibrillary tangles. Currently no therapy halts the underlying neurodegeneration in AD patients. Proteotoxic accumulation of Aβ is a central pathogenic event therefore, strategies that enhance its clearance represent a compelling therapeutic avenue. Rapamycin (sirolimus), an FDA-approved allosteric inhibitor of the mechanistic target of rapamycin complex 1 (mTORC1) that relieves mTORC1-mediated suppression of autophagy, positioning it as an attractive drug-repurposing candidate for AD. However, it remains unclear whether rapamycins neuroprotection depends on directly reducing Aβ burden or acts through Aβ-independent mechanisms. This question, along with whether rapamycin alters specific Aβ species, has not been systematically examined in a single, genetically tractable model. Methods/Results: Using two transgenic C. elegans models of human Aβ expression a temperature-inducible, muscle-specific strain CL4176 and the pan-neuronal strain CL2355. We exposed C. elegans to 20 μM rapamycin the lowest, nontoxic concentration to produce a protective effect. Rapamycin treatment delayed Aβ induced paralysis in log-rank p = 0.0001) and improved crawling and swimming locomotion parameters. In the pan-neuronal CL2355 strain, rapamycin rescued the Aβ induced chemotaxis deficit (one-way ANOVA, p = 0.008) without altering chemotaxis in the non-transgenic CL2122 control. Rapamycin also extended Kaplan Meier survival in CL2355 and preserved locomotor health span, delaying the trajectory of age related motor decline. At the molecular level, rapamycin did not significantly affect Aβ burden. Conclusion: Rapamycin provides broad-spectrum and Aβ-selective neuroprotection across muscle and neuron expressing C. elegans models of Aβ proteotoxicity, extending from paralysis and locomotion to chemosensory behavior, longevity, and health span.
Competing Interest Statement
The authors have declared no competing interest.
Funder Information Declared
CVMBS Brain Research and Education Fund
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
来源:bioRxiv 神经科学 · biorxiv.org